¼¼°èÀÇ È£¸£¸ó ´ëü ¿ä¹ý ½ÃÀå - ±Ô¸ð, Á¡À¯À², ¼ºÀå ºÐ¼® : Ä¡·á À¯Çüº°, ÀûÀÀÁõº°, Áö¿ªº° »ê¾÷ ¿¹Ãø(2025-2032³â)
Hormone Replacement Therapy Market Size, Share, Growth Analysis, By Therapy Type, By Indication, By Region - Industry Forecast 2025-2032
È£¸£¸ó ´ëü ¿ä¹ý(HRT) ¼¼°è ½ÃÀå ±Ô¸ð´Â 2023³â 289¾ï 7,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â 312¾ï 3,000¸¸ ´Þ·¯¿¡¼ 2032³â¿¡´Â 563¾ï 5,000¸¸ ´Þ·¯·Î ¼ºÀåÇØ ¿¹Ãø±â°£(2025- 2032³â)ÀÇ CAGRÀº 7.8%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.
È£¸£¸ó ´ëü ¿ä¹ý(HRT) ½ÃÀåÀº ÁÖ·Î È«Á¶ ¹× °ñ´Ù°øÁõ À§Çè°ú °°Àº Æó°æ±â °ü·Ã Áõ»óÀÇ Ä¡·á¿¡¼ ¿À·£ È¿´ÉÀ¸·Î ÇöÀúÇÑ ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. ´ë´Ù¼ö´Â ³²¼ºÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ ¿¬·ÉÃþ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ´Ù¸¥ È£¸£¸ó °ü·Ã Áúȯ¿¡ ´ëÇÑ Àνİú À¯º´·ü Áõ°¡°¡ ´õ¿í ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ °©»ó¼± Çùȸ´Â ¹Ì±¹ÀÎÀÇ 12%°¡ Æò»ý µ¿¾È °©»ó¼± ÁúȯÀ» °æÇèÇÑ´Ù°í º¸°íÇϰí ÀÖ½À´Ï´Ù. COVID-19 °¨¿°°ú »ç¸ÁÀÇ À§ÇèÀ» ³·Ãâ °¡´É¼ºÀÌ ½Ã»çµÇ°í ÀÖ½À´Ï´Ù.±× °á°ú HRT ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È °ßÁ¶ÇÑ È®´ë°¡ ¿¹»óµË´Ï´Ù.
¸ñÂ÷
¼Ò°³
- Á¶»çÀÇ ¸ñÀû
- Á¶»ç ¹üÀ§
- Á¤ÀÇ
Á¶»ç ¹æ¹ý
- Á¤º¸ Á¶´Þ
- 2Â÷ µ¥ÀÌÅÍ¿Í 1Â÷ µ¥ÀÌÅÍÀÇ ¹æ¹ý
- ½ÃÀå ±Ô¸ð ¿¹Ãø
- ½ÃÀåÀÇ ÀüÁ¦Á¶°Ç°ú Á¦ÇÑ
ÁÖ¿ä ¿ä¾à
- ¼¼°è ½ÃÀå Àü¸Á
- °ø±Þ°ú ¼ö¿ä µ¿Ç⠺м®
- ºÎ¹®º° ±âȸ ºÐ¼®
½ÃÀå ¿ªÇаú Àü¸Á
- ½ÃÀå °³¿ä
- ½ÃÀå ±Ô¸ð
- ½ÃÀå ¿ªÇÐ
- ¼ºÀå ÃËÁø¿äÀΰú ±âȸ
- ¾ïÁ¦¿äÀΰú °úÁ¦
- Porter's Five Forces ºÐ¼®
ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®
- Á߿伺°ø¿äÀÎ
- °æÀïµµ
- ÁÖ¿ä ÅõÀÚ ±âȸ
- ½ÃÀå »ýŰè
- ½ÃÀåÀÇ ¸Å·Â Áö¼ö(2024³â)
- PESTEL ºÐ¼®
- °Å½Ã°æÁ¦ÁöÇ¥
- ¹ë·ùüÀÎ ºÐ¼®
- °¡°Ý ºÐ¼®
- ±ÔÁ¦ ºÐ¼®
- »ç·Ê ¿¬±¸ ºÐ¼®
- ƯÇ㠺м®
Ä¡·áÀ¯Çü¿¡ µû¸¥ ¼¼°è È£¸£¸ó ´ëü ¿ä¹ý(HRT) ½ÃÀå ±Ô¸ð & CAGR(2025-2032³â)
- ½ÃÀå °³¿ä
- ¿¡½ºÆ®·Î°Õ°ú º´¿ë ´ëü ¿ä¹ý
- °©»ó¼± È£¸£¸ó ´ëü ¿ä¹ý
- ¼ºÀå È£¸£¸ó ´ëü ¿ä¹ý
- Å×½ºÅ佺Å׷Рȣ¸£¸ó ´ëü ¿ä¹ý
ÀûÀÀÁõ¿¡ ÀÇÇÑ ¼¼°è È£¸£¸ó ´ëü ¿ä¹ý(HRT) ½ÃÀå ±Ô¸ð & CAGR(2025-2032³â)
- ½ÃÀå °³¿ä
- Æó°æ
- °©»ó¼± ±â´É ÀúÇÏÁõ
- ³²¼º ¼º¼± ±â´É ÀúÇÏÁõ
- ¼ºÀå È£¸£¸ó °áÇÌÁõ
Åõ¿©°æ·Î¿¡ ÀÇÇÑ ¼¼°èÀÇ È£¸£¸ó ´ëü ¿ä¹ý(HRT) ½ÃÀå ±Ô¸ð & CAGR(2025-2032³â)
- ½ÃÀå °³¿ä
- °æ±¸
- °æÇÇ
- ºñ°æ±¸
À¯Åëä³Î¿¡ ÀÇÇÑ ¼¼°è È£¸£¸ó ´ëü ¿ä¹ý(HRT) ½ÃÀå ±Ô¸ð & CAGR(2025-2032³â)
- ½ÃÀå °³¿ä
- º´¿ø ¾à±¹
- ¼Ò¸Å ¾à±¹?¾à±¹
- ¿Â¶óÀÎ ¾à±¹
¼¼°è È£¸£¸ó ´ëü ¿ä¹ý(HRT) ½ÃÀå ±Ô¸ð & CAGR(2025-2032³â)
- ºÏ¹Ì
- À¯·´
- µ¶ÀÏ
- ½ºÆäÀÎ
- ÇÁ¶û½º
- ¿µ±¹
- ÀÌÅ»¸®¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- Àεµ
- ÀϺ»
- Çѱ¹
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- GCC ±¹°¡
- ³²¾ÆÇÁ¸®Ä«
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
°æÀï Á¤º¸
- »óÀ§ 5°³»ç ºñ±³
- ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´×(2024³â)
- ÁÖ¿ä ½ÃÀå ±â¾÷ÀÌ Ã¤¿ëÇÑ Àü·«
- ½ÃÀåÀÇ ÃÖ±Ù µ¿Çâ
- ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â)
- ÁÖ¿ä ±â¾÷ÀÇ ±â¾÷ ÇÁ·ÎÆÄÀÏ
- Á¦Ç° Æ÷Æ®Æú¸®¿À ºÐ¼®
- ºÎ¹®º° Á¡À¯À² ºÐ¼®
¼öÀÍÀÇ Àü³â´ëºñ ºñ±³(2022-2024³â)
ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ
- Eli Lilly and Company
- Pfizer Inc.
- Novo Nordisk A/S
- AbbVie Inc.
- TherapeuticsMD Inc.
- Bayer AG
- Mylan NV(ÇöÀç ViatrisÀÇ ÀϺÎ)
- Allergan plc(ÇöÀç AbbVieÀÇ ÀϺÎ)
- Sanofi SA
- Ferring Pharmaceuticals
- Merck & Co. Inc.
- Johnson & Johnson
- Ipsen SA
- GlaxoSmithKline plc(GSK)
- Amgen Inc.
°á·Ð°ú ±ÇÀå»çÇ×
JHS
Global Hormone Replacement Therapy (HRT) Market size was valued at USD 28.97 billion in 2023 and is poised to grow from USD 31.23 billion in 2024 to USD 56.35 billion by 2032, growing at a CAGR of 7.8% during the forecast period (2025-2032).
The hormone replacement therapy (HRT) market is witnessing significant growth, primarily due to its longstanding effectiveness in treating menopause-related symptoms such as hot flashes and osteoporosis risks. This expansion is further fueled by increasing awareness and prevalence of other hormone-related conditions affecting diverse age groups, including men. The surge in thyroid disorders, with the American Thyroid Association reporting that 12% of Americans will experience thyroid disease in their lifetime, is also contributing to market growth. Long-acting human growth hormone (hGH) products are enhancing treatment options, while recent studies suggest HRT may lower the risk of COVID-19 infection and mortality. Consequently, the HRT market is poised for robust expansion during the forecast period.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hormone Replacement Therapy (Hrt) market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Hormone Replacement Therapy (Hrt) Market Segmental Analysis
Global Hormone Replacement Therapy (HRT) Market is segmented by therapy type, indication, route of administration, distribution channel and region. Based on therapy type, the market is segmented into estrogen and combinations replacement therapy, thyroid hormone replacement therapy, growth hormone replacement therapy and testosterone hormone replacement therapy. Based on indication, the market is segmented into menopause, hypothyroidism, male hypogonadism and growth hormone deficiency. Based on route of administration, the market is segmented into oral, transdermal and parenteral. Based on distribution channel, the market is segmented into hospitals pharmacies, retail pharmacies & drug stores and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Hormone Replacement Therapy (Hrt) Market
The global Hormone Replacement Therapy (HRT) market is driven by a pressing need for effective treatments among diverse patient groups, including those facing growth hormone deficiencies, menopausal symptoms in women, and hypogonadism in older men. This medication is available in various forms such as skin and buccal patches, injections, and tablets, which enhances accessibility for patients. As demand surges worldwide, manufacturers are prioritizing the development of innovative drug delivery systems, including transdermal estrogen patches and vaginal estrogen tablets. In response to safety concerns, there is a growing emphasis on low-dose estrogen therapy, alongside new gel-based formulations for estrogen patches and other delivery methods.
Restraints in the Global Hormone Replacement Therapy (Hrt) Market
The Global Hormone Replacement Therapy (HRT) market faces several restraints that may hinder its growth. Various treatment formulations, including patches, gels, capsules, and injections, are available; however, their potential side effects can be a significant deterrent. Issues such as elevated cholesterol levels, blood clots, bloating, and swelling can negatively impact patient perception and adoption. Furthermore, testosterone replacement therapy has been linked to adverse effects including benign prostatic hyperplasia, obstructive sleep apnea, and an increased risk of prostate cancer. The US FDA's concerns regarding the approved indications and the rising cardiovascular risks associated with testosterone products add another layer of complication that may impede market expansion.
Market Trends of the Global Hormone Replacement Therapy (Hrt) Market
The Global Hormone Replacement Therapy (HRT) market is witnessing a significant upward trend, fueled by rising demand in emerging nations and heightened awareness of hormone-related health issues. As more individuals recognize the benefits of HRT, pharmaceutical companies are innovating to develop advanced medications that cater to this unmet need. Notably, the aging population and increasing prevalence of menopause and associated hormone deficiencies in key markets are driving manufacturers to unveil novel product offerings, including combination therapies that enhance efficacy and patient compliance, moving away from traditional long-acting parenteral options. This evolution underscores the dynamic nature of the HRT sector.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2024
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
- Regulatory Analysis
- Case Study Analysis
- Patent Analysis
Global Hormone Replacement Therapy (HRT) Market Size by Therapy Type & CAGR (2025-2032)
- Market Overview
- Estrogen and Combinations Replacement Therapy
- Thyroid Hormone Replacement Therapy
- Growth Hormone Replacement Therapy
- Testosterone Hormone Replacement Therapy
Global Hormone Replacement Therapy (HRT) Market Size by Indication & CAGR (2025-2032)
- Market Overview
- Menopause
- Hypothyroidism
- Male Hypogonadism
- Growth Hormone Deficiency
Global Hormone Replacement Therapy (HRT) Market Size by Route Of Administration & CAGR (2025-2032)
- Market Overview
- Oral
- Transdermal
- Parenteral
Global Hormone Replacement Therapy (HRT) Market Size by Distribution Channel & CAGR (2025-2032)
- Market Overview
- Hospitals Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
Global Hormone Replacement Therapy (HRT) Market Size & CAGR (2025-2032)
- North America (Therapy Type, Indication, Route Of Administration, Distribution Channel)
- Europe (Therapy Type, Indication, Route Of Administration, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Therapy Type, Indication, Route Of Administration, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Therapy Type, Indication, Route Of Administration, Distribution Channel)
- Brazil
- Rest of Latin America
- Middle East & Africa (Therapy Type, Indication, Route Of Administration, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2024
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2024
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novo Nordisk A/S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- TherapeuticsMD Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mylan N.V. (now part of Viatris)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Allergan plc (now part of AbbVie)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ferring Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co. Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ipsen S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc (GSK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations